Valuation: TAUNS Laboratories,Inc.

Market Cap 49.78B 306M 268M 248M 229M 434M 29.3B 443M 2.98B 1.16B 14.34B 1.15B 1.12B P/E 2025
8.67x
P/E 2026 * 9.39x
Enterprise Value 56.6B 348M 305M 282M 260M 494M 33.32B 503M 3.39B 1.32B 16.31B 1.31B 1.28B EV / Sales 2025
3.23x
EV / Sales 2026 * 3.91x
Free-Float
29.82%
Yield 2025
5.2%
Yield 2026 * 7.55%
1 week+0.43%
Current month-1.06%
1 month-4.50%
3 months-8.07%
6 months-10.71%
Current year-8.25%
1 week 463
Extreme 463
474
1 month 463
Extreme 463
492
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 01/05/2014
Director of Finance/CFO 66 01/11/2018
Corporate Officer/Principal 39 01/07/2022
Director TitleAgeSince
Director/Board Member 51 01/05/2014
Director/Board Member 66 01/09/2020
Director/Board Member 53 01/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.43%-11.89% - 309M
-4.14%-8.55%+207.30%+319.92% 21.6B
-1.98%-1.36%-41.89%-23.93% 9.51B
+3.23%-2.03%+29.54%+29.55% 6.73B
-0.86%-7.63%-34.12% - 4.94B
-0.95%-4.05%+205.88%-30.48% 4.8B
+4.64%-5.77%-25.01%-32.94% 4.56B
0.00%-4.56%-25.34%-27.23% 4.06B
-0.23%-14.25%+63.32%+72.48% 3.69B
+1.21%+3.24%-18.33%-40.37% 2.56B
Average +0.09%-2.55%+34.94%+33.37% 6.28B
Weighted average by Cap. -1.15%+0.20%+80.69%+115.43%

Financials

2025 2026 *
Net sales 19.06B 117M 103M 94.89M 87.68M 166M 11.22B 170M 1.14B 443M 5.49B 440M 430M 14.76B 90.72M 79.57M 73.46M 67.88M 129M 8.69B 131M 883M 343M 4.25B 341M 333M
Net income 6.5B 39.96M 35.05M 32.36M 29.9M 56.67M 3.83B 57.81M 389M 151M 1.87B 150M 147M 5.2B 31.98M 28.05M 25.89M 23.93M 45.35M 3.06B 46.26M 311M 121M 1.5B 120M 117M
Net Debt 6.83B 41.98M 36.82M 34M 31.42M 59.55M 4.02B 60.74M 409M 159M 1.97B 158M 154M 7.99B 49.15M 43.11M 39.8M 36.77M 69.7M 4.71B 71.1M 478M 186M 2.3B 185M 181M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
09/07/26 JP¥467.00 0.00% 116,000
08/07/26 JP¥467.00 -0.64% 200,200
07/07/26 JP¥470.00 +0.64% 147,300
06/07/26 JP¥467.00 +0.43% 448,100
03/07/26 JP¥465.00 0.00% 344,600
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
467.00JPY
Average target price
420.00JPY
Spread / Average Target
-10.06%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock